It has been proposed that fixed-dose combination (FDC) polypills could reduce major acute cardiovascular events (MACE) and improve medications adherence in secondary prevention of cardiovascular disease (CVD). This editorial will address this and look at the existing evidence in the literature with a focused review on the SECURE trial.
